Skip to main content

Table 5 Outcome in ITT and clinically evaluable patients

From: Clinical and microbiological efficacy of continuous versus intermittent application of meropenem in critically ill patients: a randomized open-label controlled trial

Parameter Infusion Bolus P- value
Number of patients    
ITT 120 120  
Clinically evaluable 106 108  
Meropenem-related length of mechanical ventilation    
ITT 9 (5 to 13) 11 (6 to 17) 0.051
Clinically evaluable 9 (5 to 15) 12 (6 to 19) 0.058
Meropenem-related ICU LOS    
ITT 10 (7 to 14) 12 (7 to 19) 0.044
Clinically evaluable 10 (7 to 16.5) 13 (8 to 21) 0.042
Meropenem-related hospital LOS    
ITT 26 (17 to 38) 22 (12 to 35) 0.079
Clinically evaluable 28 (18 to 39) 25 (14 to 42) 0.412
ICU mortality    
ITT 18 (15.0%) 25 (20.8%) 0.313
Clinically evaluable 14 (11.6%) 17 (14.2%) 0.701
Hospital mortality    
ITT 21 (17.5%) 28 (23.3%) 0.337
Clinically evaluable 17 (16.0%) 19 (15.7%) 0.857
Duration of meropenem therapy (days)    
ITT 7 (5 to 8) 8 (6 to 9) 0.041
Clinically evaluable 7 (6 to 8) 8 (7 to 10) 0.035
Total dose of meropenem (g)    
ITT 24 (21 to 32) 48 (42 to 48) < 0.0001
Clinically evaluable 24 (24 to 32) 48 (42 to 60) < 0.0001
  1. Values are presented as absolute (percentage) or median (interquartile range). ICU, intensive care unit; ITT, intention-to-treat; LOS, length of stay